BIOC Key Stats
- Biocept, Inc. to Present at the 26th Annual ROTH Conference noodls 03/05 11:55 ET
- BIOCEPT INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Yahoo 02/14 14:42 ET
- Biocept, Inc. Announces Closing of Initial Public Offering noodls 02/10 21:17 ET
- Biocept, Inc. Announces Closing of Initial Public Offering GlobeNewswire 02/10 18:06 ET
- IPO roundup: 5 companies go public Wednesday Yahoo 02/05 17:34 ET
- Biocept (BIOC) IPO Opens Flat, Trades Lower Street Insider 02/05 11:44 ET
- Biocept, Inc. Announces Pricing of Initial Public Offering noodls 02/05 08:22 ET
- BIOCLINICA INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tr 03/14 07:42 ET
- BioClinica Inc and JLL Partners Inc Announce Successful Completion of Tender Offer noodls 03/13 16:31 ET
- BioClinica, Inc. and JLL Partners, Inc. Announce Successful Completion of Tender Offer Business Wire 03/12 07:00 ET
BIOC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Biocept is up N/A over the last year vs S&P 500 Total Return up 24.21%, Icon up 47.43%, and Agilent Technologies up 36.47%.
Balance Sheet View Statement
Pro Ratings for BIOC
Pro Strategies Featuring BIOC
Did Biocept make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Diagnostics & Research
- Headquarters Country: United States
- Headquarters State/Province: California
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Biocept Inc is a cancer diagnostics company. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample.